SCHEMBL8648071

SCHEMBL8648071

Nc1ccc(Cl)cc1OS(=O)(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.43
TSHR P16473 4/20 0.43
CYP3A4 P08684 4/20 0.43
ALOX15 P16050 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
TDP1 Q9NUW8 1/20 0.43
HPGD P15428 4/20 0.43
HSD17B10 Q99714 2/20 0.43
RECQL P46063 2/20 0.43
THRB P10828 1/20 0.43
CASP1 P29466 1/20 0.43
CYP2C9 P11712 3/20 0.42
TRPV4 Q9HBA0 1/20 0.40
ALOX12 P18054 1/20 0.39
MAPK1 P28482 1/20 0.39
ABL1 P00519 1/20 0.39
TP53 P04637 1/20 0.38
FADS1 O60427 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8648069 0.85 CYP3A4 (0.46) ALDH1A1TSHRCYP3A4ALOX15SMN1; SMN2
SCHEMBL9639874 0.81 ALDH1A1 (0.50) ALDH1A1TSHRCYP3A4ALOX15TDP1
SCHEMBL11028747 0.79 GAA (0.47) ALDH1A1TSHRCYP3A4ALOX15HPGD
SCHEMBL7763074 0.79 CISD1 (0.41) ALDH1A1TSHRCYP3A4ALOX15HPGD
SCHEMBL11490908 0.78 CA1 (0.50) ALDH1A1TSHRCYP3A4ALOX15SMN1; SMN2
SCHEMBL8018538 0.78 CA1 (0.38) ALDH1A1TSHRCYP3A4ALOX15SMN1; SMN2
SCHEMBL8997103 0.78 PKM (0.41) ALDH1A1TSHRCYP3A4ALOX15HPGD
SCHEMBL1062499 0.77 CYP2C9 (0.51) TSHRSMN1; SMN2TDP1HPGDCYP2C9
SCHEMBL10708307 0.76 ALDH1A1 (0.39) ALDH1A1TSHRCYP3A4ALOX15TDP1
SCHEMBL10448986 0.76 CYP2C9 (0.39) ALDH1A1ALOX15SMN1; SMN2HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0555036-B1 Antitumor compositions and methods of treatment LILLY CO ELI (US) 1998-09-09 EP disclosed
US-5262440-A Treatment of neoplasms ELI LILLY AND COMPANY (US) 1993-11-16 US disclosed
US-5254582-A Using n-((3,4-dichlorophenyl)amino)carbonyl)-2,3-dihydro-benzofuran-5-sulfonamide ELI LILLY AND COMPANY (US) 1993-10-19 US disclosed
EP-0555036-A2 Antitumor compositions and methods of treatment ELI LILLY AND COMPANY (US) 1993-08-11 EP disclosed
EP-0546763-A1 Antitumor compositions and methods of treatment ELI LILLY AND COMPANY (US) 1993-06-16 EP disclosed